Monographie - Methotrexate sodium

Methotrexate sodium

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Abitrexate	Dél-Afrikai Köztársaság
Antifolan	Románia
Artrait	Argentína
Bendatrexat	Németország
Biometrox	Brazília
Ebetrex	Svájc
Ebetrexate	Ausztria
Emthexat	Törökország
Emthexate	Belgium, Dél-Afrikai Köztársaság, Hollandia, Spanyolország
Ledertrexate	Belgium, Franciaország, Luxemburg, Marokkó
Maxtrex	Nagy-Britannia
Metex	Németország, Norvégia
Methoblastin	Dél-Afrikai Köztársaság
Methotrexamed	Németország
Methotrexate	Franciaország
Metoject	Chile, Dánia, Finnország, Franciaország, Hollandia, Nagy-Britannia, Spanyolország, Svájc, Svédország
Metotrexato	Chile
Trexan	Finnország
Trexat	Németország

Irodalom : Methotrexate sodium

	Type	publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31	Napló	Zhang Y, Xu QA, Trissel LA, Gilbert DL. Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution. Hosp Pharm 1996 ; 31: 965-970.
57	Napló	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Napló	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Napló	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110	Napló	Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 1989 ; 54: 181-189.
145	Napló	Lorillon P, Corbel JC, Mordelet MF, Basle B, Guesnier LR. Photosensibility of 5-fluorouracile and methotrexate in translucent or opaque perfusers. J Pharm Clin 1992 ; 11: 285-295.
150	Napló	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
162	Napló	Benaji B, Dine T, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Gressier B, Cazin M, Cazin JC. Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures. Int J Pharm 1994 ; 105: 83-87.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
184	Napló	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Napló	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Napló	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Napló	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
431	Napló	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
491	Napló	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Napló	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
739	Napló	Cradock JC, Kleinmann LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm 1978 ; 35: 402-406.
763	Napló	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
859	Napló	Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ. Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment. Nor Pharm Acta 1983 ; 45: 61-67.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
978	Napló	Dick DM, Woloschuk DMM. Methotrexate and cytarabine for intrathecal administration. Can J Hosp Pharm 1994 ; 47: 147.
1021	Napló	Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J. Methotrexate in solutions - A stability test for the hospital pharmacy. J Clin Hosp Pharm 1986 ; 11: 343-348.
1028	Napló	Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm 1984 ; 41: 1802-1806.
1088	Napló	Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH. Drug trapping in intravenous infusion side arms. JAMA 1984 ; 252: 2392.
1155	Napló	Wright MP, Newton JM. Stability of methotrexate injection in prefilled plastic disposable syringes. Int J Pharm 1988 ; 45: 237-244.
1158	Napló	McElnay JC, Elliott DS, Cartwright-Shamoon J, D?Arcy PF. Stability of methotrexate and vinblastine in burette administration sets. Int J Pharm 1988 ; 47: 239-247.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1469	Napló	Jacolot A, Arnaud P, Lecompte D, Alamercery S, Caroff E, Naveau C, Guillot T, Bousselet M, Brion F. Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days. Int J Pharm 1996 ; 128: 283-286.
1501	Napló	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratórium	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1661	Napló	Trissel LA, King KM, Zhang Y, Wood AM. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use. J Oncol Pharm Practice 2002 ; 8: 27-32.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3275	Napló	D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate Am J Health-Syst Pharm 2012 ; 69: 232-240.
3474	Laboratórium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3580	Laboratórium	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3637	Laboratórium	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3670	Napló	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3731	Napló	Chatterji D.C, Gallelli J.F. Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci 1978 ; 67, 4: 526-530.
3980	Napló	Nissen K.B, Jorgensen L.B, Berg D.L, Andersen G. Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities. Am J Health-Syst Pharm 2017 ; 74,9: e211-e223
4154	Laboratórium	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4578	Tézis	Respaud R. Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques 2011
4641	Napló	Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P. Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies. Eur J Pharm Sci 2021 ;167: 106039.